Objective. Many patients with systemic lupus erythematosus (SLE) and fibrom
yalgia (FM) may spend less time exposed to the sun than healthy individuals
and thus might have low vitamin D levels. It is known that hydroxychloroqu
ine (HCQ) inhibits conversion of 25(OH)- to 1,25(OH)(2)-vitamin D both in v
itro and in patients with sarcoidosis. We assessed winter serum 25(OH)- and
1,25(OH)(2)-vitamin D levels in patients with SLE and FM.
Methods. We recruited 25 consecutive female SLE and 25 female FM patients i
n London. Ontario, between January and March 2000. Subjects completed a bri
ef questionnaire, Serum levels of 25(OH)-, 1,25(OH)(2)-vitamin D, and parat
hyroid hormone (PTH) were measured.
Results. In SLE pa tents mean 25(OH)-vitamin D was 46.5 nmol/l and mean 1,2
5(OH)(2)-vitamin D was 74.4 pmol/l. In FM patients these means were 51.5 nm
ol/l and 90.1 pmol/l, respectively. Serum 25(OH)-vitamin D levels did not s
ignificantly differ between SLE and FM patients, nor after adjusting for ag
e and vitamin D. milk consumption. and sun block use. In 14 of the SLE pati
ents and 12 of the FM patients 25(OH)-vitamin D levels <50 nmol/l were foun
d. SLE patients not using vitamin D supplements had lower 25(OH)-vitamin D
levels than those who did. 1,25 (OH)(2)- vitamin D tended to be lower in th
e SLE compared to the FM patients. This difference could be attributed to H
CQ use: HCQ users (n = 17) had lower 1,25(OH)(2)-vitamin D levels than nonu
sers (n = 33); the mean adjusted difference was 24.4 pmol/l (95% CI 2.8-49.
9).
Conclusion. Half the SLE and FM patients had 25(OH)-vitamin D levels <50 nm
ol/l, a level at which PTH stimulation occurs. Our data suggest that in SLE
patients HCQ might inhibit conversion of 25(OH)-vitamin D to 1,25(OH)(2)-v
itamin D.